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Abstract Normal mitochondrial dynamics consist of fis-
sion and fusion events giving rise to new mitochondria, a
process termed mitochondrial biogenesis. However, several
neurodegenerative disorders manifest aberrant mitochon-
drial dynamics, resulting in morphological abnormalities
often associated with deficits in mitochondrial mobility and
cell bioenergetics. Rarely, dysfunctional mitochondrial
occur in a familial pattern due to genetic mutations, but
much more commonly patients manifest sporadic forms of
mitochondrial disability presumably related to a complex
set of interactions of multiple genes (or their products) with
environmental factors (G 9 E). Recent studies have shown
that generation of excessive nitric oxide (NO), in part due
to generation of oligomers of amyloid-b (Ab) protein or
overactivity of the NMDA-subtype of glutamate receptor,
can augment mitochondrial fission, leading to frank frag-
mentation of the mitochondria. S-Nitrosylation, a covalent
redox reaction of NO with specific protein thiol groups,
represents one mechanism contributing to NO-induced
mitochondrial fragmentation, bioenergetic failure, synaptic
damage, and eventually neuronal apoptosis. Here, we
summarize our evidence in Alzheimer’s disease (AD)
patients and animal models showing that NO contributes to
mitochondrial fragmentation via S-nitrosylation of dyn-
amin-related protein 1 (Drp1), a protein involved in mito-
chondrial fission. These findings may provide a new target
for drug development in AD. Additionally, we review
emerging evidence that redox reactions triggered by
excessive levels of NO can contribute to protein misfold-
ing, the hallmark of a number of neurodegenerative dis-
orders, including AD and Parkinson’s disease. For
example, S-nitrosylation of parkin disrupts its E3 ubiquitin
ligase activity, and thereby affects Lewy body formation
and neuronal cell death.
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Introduction
Brains with neurodegenerative diseases often manifest
excessive generation of reactive nitrogen species (RNS)
and reactive oxygen species (ROS), which can contribute
to neuronal cell injury and death via a series of redox
reactions [1–5]. While many intra- and extracellular mol-
ecules may participate in neuronal injury, accumulation of
nitrosative stress due to excessive generation of nitric oxide
(NO) appears to be a potential factor contributing to neu-
ronal cell damage and death [6, 7]. A well-established
model for NO production entails a central role of the
N-methyl-D-aspartate (NMDA)-type glutamate receptors in
nervous system. Excessive activation of NMDA receptors
drives Ca2? influx, which in turn activates neuronal NO
synthase (nNOS) as well as the generation of ROS [8, 9].
Accumulating evidence suggests that NO can mediate both
protective and neurotoxic effects by redox reactions with
cysteine residues of target proteins to form S-nitrosothiols
(SNOs), a process termed S-nitrosylation because of its
effects on the chemical biology of protein function.
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Importantly, normal mitochondrial respiration may also
generate free radicals, principally ROS, and one such
molecule, superoxide anion (O2
.-), reacts rapidly with free
radical NO to form the very toxic product peroxynitrite
(ONOO-) [10, 11].
Production of NO from inducible NOS (iNOS) can also
contribute to the pathogenesis of neurodegenerative dis-
eases, including Alzheimer’s disease (AD) [12, 13]. A clas-
sic feature of AD pathology is the generation of b-amyloid
(Ab) peptides. Recently, several lines of evidence have
suggested that soluble oligomers of Ab represent the most
toxic form of the peptide [14]. Consistent with this notion,
Ab oligomers, but not fibrillar Ab, induce high expression of
iNOS in astrocytes and thus generation of NO [15]. Addi-
tionally, Ab is known to inhibit glutamate re-uptake, at least
in part via generation of ROS; this can lead to pathological
activation of NMDA receptors, thereby disturbing synaptic
function in AD [16–18]. Excessive stimulation of NMDA
receptors also leads to activation of nNOS, as discussed
above, thus representing another source of NO emanating
from Ab oligomers.
Dysfunction in mitochondria represents another hall-
mark of neurodegenerative diseases. For example, patients
with early stage AD regularly exhibit declining mito-
chondrial energy metabolism and ATP production, which
may subsequently cause synaptic loss and neuronal damage
[19–21]. Interestingly, neurons in AD and other neurode-
generative brains often display abnormal mitochondrial
morphology [22, 23].
Normally, mitochondria are known to continuously
undergo fission and fusion (known as mitochondrial
dynamics) to generate smaller organelles or elongated,
tubular structures, respectively. This normal mitochondrial
fission and fusion can facilitate formation of new mito-
chondria (biogenesis), repair of defective mitochondrial
DNA through mixing, and redistribution of mitochondria to
sites requiring high-energy production [24–26]. Conversely,
an imbalance in fission or fusion initiates malfunctions
in mitochondrial morphology and bioenergetics, and may
thus contribute to neuronal injury during neurodegeneration
[26–28]. Dysfunction in mitochondrial dynamics can result
from either (i) rare genetic mutations in fission- or fusion-
related genes, as occurs in Charcot-Marie-Tooth (CMT)
Disease and Autosomal Dominant Optic Atrophy (ADOA)
[29, 30], or (ii) posttranslational changes to the fission or
fusion proteins. In particular, a posttranslational modifica-
tion engendered by nitrosative/oxidative stress may well
account for the more common sporadic cases of the disease
[31, 32]. Hence, a key theme of this article is the hypothesis
that excessive accumulation of nitrosative stress contributes
to abnormal mitochondrial morphology in brains of neuro-
degenerative patients. In this review, we discuss a specific
example, showing that S-nitrosylation of the mitochondrial
fission protein dynamin-related protein 1 (Drp1) contributes
to excessive mitochondrial fission/fragmentation, synaptic
injury, and neuronal apoptosis in neurodegenerative diseases
such as AD. We also review evidence that S-nitrosylation of
critical proteins can cause protein misfolding and contribute
to the aggregation of aberrant proteins seen in many neuro-
degenerative disorders, including AD and Parkinson’s dis-
ease (PD).
Mitochondrial fission/fusion machinery in nerve cells
Neurons are particularly vulnerable to mitochondrial
defects because they require high levels of energy for their
survival and specialized function. Mitochondrial biogene-
sis is required in regions that demand high concentrations
of ATP, especially the synapse. The distribution of mito-
chondria at the nerve terminal can control synaptic trans-
mission and structure [24, 33, 34].
In healthy neurons, the fission/fusion machinery proteins
maintain mitochondrial integrity and insure their presence at
critical locations. These proteins includes Drp1 and Fis1,
acting as fission proteins, and Mitofusin (Mfn) and Opa1,
operating as fusion proteins [35]. In both familial and spo-
radic neurodegenerative conditions, abnormal mitochondria
regularly appear in the brain as a result of dysfunction in the
fission/fusion machinery. Genetic mutations in Mfn2 can
cause CMT disease, a hereditary peripheral neuropathy that
affects both motor and sensory neurons [30, 36]. Mutations
in Opa1 cause ADOA, characterized by the loss of retinal
ganglion cells and the optic nerve, representing their axons
[29]. Recently, Waterham et al. described a heterozygous,
dominant-negative mutation of Drp1 in a patient whose
symptoms were broadly similar to those of CMT neuropathy
and ADOA [37]. Drp1 includes four distinct structural
domains: an N-terminal GTPase domain, a dynamin-like
middle domain, an insert B domain, and a C-terminal GED
domain. The mutation (Ala 395 to Asp) was found in the
middle domain of Drp1. This case study further suggested
that a defect in mitochondrial fission may have more severe
consequences than those of fusion defects, since the Drp1
mutation caused a much earlier onset (prenatal) and fatal
outcome. Additionally, it is apparent that the balance
between fission and fusion is critical for normal function of
mitochondria and determination of phenotype in disease.
These fission/fusion proteins are widely expressed in human
tissues, clearly supporting the notion that neurons are par-
ticularly sensitive to mitochondrial dysfunction.
Dysregulation of mitochondrial dynamics in AD
An estimated 26 million people globally have AD, which is
thought to be the most common form of dementia. In AD
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brains, neuronal loss in the hippocampus and cerebral
cortex mainly accounts for the cognitive decline. Degen-
erating AD brains contain aberrant accumulations of mis-
folded, aggregated proteins—Ab and tau—which can
adversely affect neuronal connectivity and plasticity, and
trigger cell death signaling pathways. These aggregates are
recognized as either intracellular neurofibrillary tangles,
which contain hyperphosphorylated tau, or extracellular
plaques, which contain Ab. b-Secretase and c-secretase
proteolytically cleave amyloid precursor protein (APP) in
its transmembrane region to generate Ab. It is currently
thought that soluble oligomers of misfolded protein are
pathogenic and that the large aggregates may actually be an
attempt by the cell to wall off the aberrant proteins
(although such aggregates could potentially be toxic by
location or if not contained by the proper chaperones).
Interestingly, a recent study showed that an N-terminal
fragment of APP may also contribute to neurodegeneration
in AD models [38].
Emerging evidence suggests that mitochondrial dys-
function plays a prominent role in the pathogenesis of AD
[39]. Analyses of autopsy and biopsy samples revealed that
mitochondria isolated from AD brains exhibit diminished
respiratory capacity [20], and that AD neurons contain a
number of mitochondria with fractured cristae [40].
Additionally, electron-microscopic studies have described
an increase in mitochondrial fragmentation in human AD
brains [22, 23]. In cell-based experiments, Ab production
resulted in the appearance of fragmented and abnormally
distributed mitochondria [27, 41], suggesting that Ab
(possibly in the form of soluble oligomers) may trigger
excessive mitochondrial fission in AD patients. Pathologi-
cal forms of tau may also contribute to mitochondrial
fragmentation in AD brains since expression of caspase-
cleaved tau induced mitochondrial fission in a calcineurin-
dependent manner [42].
Similarly, dysfunction in mitochondrial integrity is
associated with PD [43]. For instance, the Parkinsonian
neurotoxins, rotenone and l-methyl-4-phenyl-pyridinium
ion (MPP?), which inhibit complex I of the mitochondrial
electron transport chain, can induce excessive mitochon-
drial fragmentation and cell death [27]. Additionally,
multiple groups recently observed that a deficiency in
familial PD-related proteins, such as parkin and PINK1, led
to the appearance of mitochondrial pathology [44–47].
Exogenous expression of mitochondrial fusion proteins,
Mfn2 and OPA1, or dominant negative Drp1 rescued the
altered mitochondrial morphology, suggesting that parkin
or PINK1 deficiency promoted mitochondrial fragmenta-
tion [46]. Interestingly, Drp1 seems to activate autophagy/
mitophagy pathways for morphologic remodeling of
mitochondria in PINK1-deficient neuroblastoma cells [48].
Taken together, dysregulation of mitochondrial dynamics
may contribute to a common pathway leading to the patho-
genesis of several neurodegenerative diseases, including
AD and PD.
NMDA receptor signaling pathways induce
generation of RNS/ROS
The amino acid glutamate is the major excitatory neuro-
transmitter in the brain. Excitatory neurotransmission plays
an important role in the normal development and plasticity
of synapses, and for some forms of learning or memory;
however, excessive activation of glutamate receptors is
implicated in neuronal damage in many neurological dis-
orders ranging from acute hypoxic-ischemic brain injury to
chronic neurodegenerative diseases. Among several fami-
lies of glutamate receptors, the NMDA receptor has long
attracted attention because it has several properties that set
it apart from the other receptors. One such characteristic is
that NMDA receptor-coupled channels are highly perme-
able to Ca2?, triggering Ca2? entry after ligand binding if
the cell is first depolarized in order to relieve channel block
by Mg2? [49, 50]. Subsequent binding of Ca2? to various
intracellular molecules can lead to many significant con-
sequences. In particular, excessive activation of NMDA
receptors leads to the production of damaging free radicals
(e.g., NO and ROS) and other enzymatic processes, con-
tributing to cell injury and death [6, 11, 51–54]. It is cur-
rently thought that overstimulation of extrasynaptic NMDA
receptors mediates this neuronal damage, while, in con-
trast, synaptic activity predominantly activates survival
pathways [55–57]. Intense hyperstimulation of excitatory
receptors leads to necrotic cell death, but milder or chronic
overstimulation can result in apoptotic or other forms of
cell death [53, 54, 58]. Furthermore, Ab oligomers induce
neuronal synaptic damage via an NMDA receptor-depen-
dent mechanism [59].
Excessive activation of glutamate receptors has been
implicated in neuronal damage in many neurological dis-
orders. John Olney coined the term ‘‘excitotoxicity’’ to
describe this phenomenon [60, 61]. This form of toxicity is
mediated at least in part by excessive activation of NMDA-
type receptors [6, 7, 62], resulting in excessive Ca2? influx
through a receptor’s associated ion channel. Increased
levels of neuronal Ca2?, in conjunction with the Ca2?-
binding protein CaM, trigger the activation of nNOS and
subsequent generation of NO from the amino acid L-argi-
nine [8, 63]. NO is a gaseous free radical (thus highly
diffusible) and a key molecule that plays a vital role in
normal signal transduction but in excess can lead to neu-
ronal cell damage and death. The diversity of NO effects
on neuronal survival can also be caused by the formation of
different NO species or intermediates: NO radical (NO),
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nitrosonium cation (NO?), nitroxyl anion (NO-, with high
energy singlet and lower energy triplet forms) [11].
Nitrosative stress regulates protein misfolding
and neuronal cell death
Early investigations indicated that NO participates in cel-
lular signaling pathways, which regulate broad aspects of
brain function, including synaptic plasticity, normal
development, and neuronal cell death [51, 64–66]. In
general, NO exerts physiological and some pathophysio-
logical effects via stimulation of guanylate cyclase to form
cyclic guanosine-30,50-monophosphate (cGMP) or through
S-nitros(yl)ation of regulatory protein thiol groups [9, 11,
67–70]. S-Nitrosylation is the covalent redox reaction of an
NO group with a critical cysteine thiol/sulfhydryl (RSH or,
more properly, thiolate anion, RS-) to form an S-nitroso-
thiol derivative (R-SNO). Such modification modulates the
function of a broad spectrum of mammalian, plant, and
microbial proteins. In general, a consensus motif of amino
acids comprised of nucleophilic residues (generally an acid
and a base) surround a critical cysteine, which increases the
cysteine sulfhydryl’s susceptibility to S-nitrosylation [71,
72]. Our group first identified the physiological relevance
of S-nitrosylation by showing that NO and related RNS
exert paradoxical effects via redox-based mechanisms—
NO is neuroprotective via S-nitrosylation of NMDA
receptors (as well as other subsequently discovered targets,
including caspases), and yet can also be neurodestructive
by formation of peroxynitrite (or, as later discovered,
reaction with additional molecules such as MMP-9, parkin,
peroxiredoxin II, Drp1, protein-disulfide isomerase (PDI),
and GAPDH) [11, 73–80]. Over the past decade, accu-
mulating evidence has suggested that S-nitrosylation can
regulate the biological activity of a great variety of pro-
teins, in some ways akin to phosphorylation [11, 72,
79–92]. Chemically, NO is often a good ‘‘leaving group,’’
facilitating further oxidation of critical thiols to disulfide
bonds among neighboring (vicinal) cysteine residues or,
via reaction with ROS, to sulfenic (-SOH), sulfinic
(-SO2H), or sulfonic (-SO3H) acid derivatization of the
protein [79, 82, 83, 93]. Alternatively, S-nitrosylation may
possibly produce a nitroxyl disulfide, in which the NO
group is shared by close or vincinal cysteine thiols [94].
In prior work, analyses of mice deficient in either nNOS
or iNOS confirmed that NO is an important mediator of cell
injury and death after excitotoxic stimulation; excessive
NO generated from nNOS or iNOS is detrimental to neu-
ronal survival [95, 96]. In addition, inhibition of NOS
activity ameliorates the progression of disease pathology in
animal models of AD, PD, and Amyotrophic Lateral
Sclerosis, suggesting that excess generation of NO plays a
pivotal role in the pathogenesis of several neurodegenera-
tive diseases [97–100].
A common theme in many neurodegenerative disorders
is the finding of abnormal aggregates of misfolded proteins.
Recent findings have implied that NO-related species may
significantly participate in the process of protein misfold-
ing through protein S-nitrosylation under degenerative
conditions. Specifically, we and others recently mounted
physiological and chemical evidence that S-nitrosylation
modulates the (i) ubiquitin E3 ligase activity of parkin [81,
82, 101], and (ii) chaperone and isomerase activities of PDI
[83], contributing to protein misfolding and neurotoxicity
in models of neurodegenerative disorders (Fig. 1). Muta-
tions in the parkin gene can cause autosomal recessive
juvenile Parkinsonism (ARJP), accounting for some cases
of hereditary PD manifest in young patients with onset
beginning anywhere from the teenage years through the
40s [102–104]. As an E3 ubiquitin ligase, parkin catalyzes
formation of polyubiquitin chains on substrate proteins
(e.g., synphilin-1 and Pael-R); these ubiquitin chains rep-
resent the signal for proteasomal degradation of the pro-
teins. Clearance of misfolded or aberrant proteins requires,
at least in part, the activity of the ubiquitin-proteasome
system (UPS). We and others found evidence for S-nitro-
sylation of parkin (forming SNO-parkin) not only in rodent
models of PD but also in the brains of human patients with
PD and the related a-synucleinopathy, diffuse Lewy body
disease (DLBD). SNO-parkin initially stimulates ubiquitin
E3 ligase activity, resulting in enhanced ubiquitination as
observed in Lewy bodies, followed by a decrease in
enzyme activity, producing a futile cycle of dysfunctional
UPS [82, 101, 105]. Moreover, S-nitrosylation appears to
compromise the neuroprotective effect of parkin [81].
These mechanisms involve S-nitrosylation of critical cys-
teine residues in the first RING domain of parkin [82].
Nitrosative and oxidative stress can also alter the solubility
of parkin via posttranslational modification of cysteine
residues, which may concomitantly compromise its pro-
tective function [106–108].
During protein folding in the ER, PDI can introduce
disulfide bonds into proteins (oxidation), break disulfide
bonds (reduction), and catalyze thiol/disulfide exchange
(isomerization), thus facilitating disulfide bond formation,
rearrangement reactions, and structural stability [109]. In
many neurodegenerative disorders as well as in cerebral
ischemia, the accumulation of immature and denatured
proteins results in ER dysfunction [110–113], and upreg-
ulation of PDI represents an adaptive response known as
the unfolded protein response (UPR), which promotes
protein refolding and may contribute to neuroprotection
[111, 114–116]. In a recent study, we reported that the
S-nitrosylation of PDI (to form SNO-PDI) disrupts
this neuroprotective role [83]. We found that PDI is
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S-nitrosylated in the brains of virtually all cases examined
of sporadic AD and PD. SNO-PDI formation led to the
accumulation of polyubiquitinated/misfolded proteins and
activation of the UPR. Moreover, S-nitrosylation abrogated
the inhibitory effect of PDI on aggregation of proteins
observed in Lewy body inclusions [83, 117]. S-Nitrosyla-
tion of PDI also prevented its attenuation of neuronal cell
death triggered by ER stress, misfolded proteins, or pro-
teasome inhibition.
Nitrosative stress can also result in defects in mito-
chondrial function. For example, NO affects mitochondrial
respiration by reversibly inhibiting complexes I and IV
[118, 119]. Mitochondria thus compromised will release
ROS, and this in turn could contribute to brain aging and/or
pathological conditions associated with neurodegenerative
diseases. Additionally, increased nitrosative and oxidative
stress can elicit dysfunction of mitochondrial dynamics
(fission and fusion events) [27, 120, 121]. However, until
recently little was known regarding the molecular and
pathogenic mechanisms by which NO contributes to the
formation of fragmented mitochondria. Our recent findings
have shed light on the molecular events underlying this
relationship, particularly in AD. Specifically, we recently
discovered physiological and chemical evidence that
S-nitrosylation modulates the GTPase activity of Drp1,
thus contributing to mitochondrial fragmentation, bioen-
ergetic impairment, synaptic damage, and eventually frank
neuronal loss in models of AD.
S-Nitrosylation of Drp1 mediates mitochondrial
fission and neurotoxicity in cell models of AD
In addition to the rare genetic mutations seen in the genes
encoding mitochondrial fission and fusion proteins, recent
studies have demonstrated that posttranslational modifi-
cation of these molecules can contribute to altered
mitochondria dynamics. For example, phosphorylation,
ubiquitination, sumoylation, and proteolytic cleavage of
Drp1 regulate mitochondrial fission by affecting Drp1
activity, at least in cell culture systems [122–129]. Exces-
sive activation of mitochondrial fission or fusion proteins
by posttranslational modification was posited to contribute
to neurodegeneration by compromising mitochondrial
function. Interestingly, along these lines, we recently
reported that excessive NO can also lead to S-nitrosylation
of Drp1 at Cys644 [31]. Cys644 resides within the GTPase
effector domain (GED) of Drp1, which influences both
GTPase activity and oligomer formation of Drp1 [130–
133]. S-Nitrosylation of Drp1 (forming SNO-Drp1) induces
formation of Drp1 dimers, which function as building
blocks for tetramers and higher order structures of Drp1,
and activates Drp1 GTPase activity; however, substitution
of Cys644 to Ala (C644A) abrogated these effects of NO.
We further demonstrated that exposure to oligomeric Ab
peptide results in formation of SNO-Drp1 in cell culture
models (Fig. 2). Moreover, we and others have observed
that Drp1 is S-nitrosylated in the brains of virtually all
cases of sporadic AD [23, 31]. In order to determine the
consequences of S-nitrosylated Drp1 in neurons, we
exposed cultured cerebrocortical neurons to the physio-
logical NO donor, SNOC, or to Ab oligomers and found
that both induced SNO-Drp1 formation and led to the
accumulation of fragmented mitochondria. Moreover,
mutation of a specific cysteine residue in Drp1 (C644A)
prevented these effects of SNOC or Ab on mitochondrial
fragmentation, consistent with the notion that SNO-Drp1
triggered excessive mitochondria fission or fragmentation.
Finally, in response to Ab, SNO-Drp1—induced mito-
chondrial fragmentation caused synaptic damage, an early
characteristic feature of AD, and eventually apoptotic
neuronal cell death. Importantly, blockade of Drp1 nitro-
sylation (using the Drp1(C644A) mutant) prevented
Ab-mediated synaptic loss and neuronal cell death,
Fig. 1 Schema of S-nitrosylated species contributing to the accumu-
lation of aberrant proteins and neuronal damage. NMDAR hyperac-
tivation triggers generation of NO/ROS. S-Nitrosylation of parkin
(forming SNO-PARK) and PDI (forming SNO-PDI) can contribute to
neuronal cell injury in part by triggering accumulation of misfolded
proteins
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suggesting that SNO-Drp1 may represent a potential ther-
apeutic target to protect neurons and their synapses in AD.
In addition to AD, SNO-Drp1 may affect the patho-
genesis of other neurodegenerative disorders, such as
Huntington’s disease (HD), as we have recently observed
nitrosylation of Drp1 in HD brains as well as in AD brains.
An expanded CAG repeat in the huntingtin (htt) gene is the
cause of HD. A potential mechanism for neurodegeneration
in HD that is triggered by mutant Htt (mtHtt) involves
mitochondrial dysfunction. Evidence for this includes
reduced activity of respiratory complexes, decreased
mitochondrial membrane potential, and changes in mito-
chondrial ultrastructure [134, 135]. Interestingly, expres-
sion of mtHtt induces mitochondrial fragmentation in Hela
cells [136], and exposure to the mitochondrial complex II
inhibitor 3-NP, which reproduces many of the pathological
features of HD, leads to mitochondria fission [137]. Fur-
thermore, accumulating evidence suggests that excitotoxic
pathways, which increase NO, may contribute to the
pathophysiology of HD [138]. Hence, it is tempting to
postulate that SNO-Drp1 may be involved in the mito-
chondrial fragmentation and neuronal injury observed in
HD.
Conclusions
Excessive nitrosative and oxidative stress triggered by
overstimulation of NMDA receptors and/or Ab production
may result in mitochondrial dysfunction, thus contributing
to synaptic damage and neuronal loss in sporadic forms of
neurodegenerative diseases. Additionally, nitrosylation
reactions can lead to aberrant and misfolded proteins in
neurodegenerative conditions. For example, S-nitrosylation
of parkin and PDI can contribute to the accumulation
of such aggregated proteins. Our recent identification of




and neuronal damage. NMDAR
hyperactivation triggers
generation of NO and
subsequent S-nitrosylation of
neuronal proteins, contributing
to synaptic damage and
eventually neuronal death.
Soluble oligomers of Ab
oligomers, known to be a key
mediator of AD pathogenesis,
can facilitate neuronal NO
production in both NMDAR-
dependent and -independent
manners. S-Nitrosylation of
Drp1 (forming SNO-Drp1) can
contribute to synaptic damage
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SNO-Drp1, triggered by oligomeric Ab, provides a mech-
anistic link between free radical production, abnormal
mitochondrial morphology, and neuronal cell injury in
neurodegenerative disorders such as AD. Elucidation of this
new pathway may lead to the development of additional
therapeutic approaches to prevent excessive mitochondrial
fission by targeted disruption or prevention of SNO-Drp1.
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